Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Louisville Hematology Highlights

R. Gale

AML and MDS Highlights & Key Takeaways

Insights from 2023 ASH Annual Meeting

T. Badar

2024 Updates on Emerging & Current Treatment of Multiple Myeloma

Indy Hematology Review

K. Anderson

Debates in AML: 7+3 Is No Longer the Standard of Care

XV Eurasian Hematology-Oncology Congress - EHOC 2024

T. Kadia

AML, MDS, and CML Highlights & Key Takeaways From ASCO®/EHA 2024

Insights from 2024 EHA Annual Meeting

T. Badar

Treatment of AML: Managing the Patient When Transplant Is Not an Opt…

Indy Hematology Review

H. Erba

ASH 2023 Summary: "The Best of Myeloma - Highlights & Key Takeaways"

Insights from 2023 ASH Annual Meeting

H. Hashmi

ASCO® 2024 Summary: "The Best of Myeloma - Review of the Top 5 Abstr…

2024 ASCO® Annual Meeting Insights Hub

H. Hashmi

Advances in Multiple Myeloma 2024: From Bench to Bedside

Dana-Farber Cancer Institute

K. Anderson

Multiple Myeloma: A Journey From Pharaoh's Times to 2024

Houston Methodist

S. Ganguly

Understanding the NPM1 Mutation in AML: Dr. Jekyll and Mr. Hyde

SOHO Brazil 2024

J. Lancet

HSCT in 2024: What Every Hematologist Needs to Know

Indy Hematology Review

R. Childs

Where I Use Azacitidine and Venetoclax in AML: Present and Future

SOHO Brazil 2024

J. Lancet

Experts Discuss the Pathophysiology, Diagnosis, and Treatment of BPD…

MyCancerHaven

R. Vij, G. Murthy

Multiple Myeloma: Not as Simple as "CRAB" Anymore

Fred Hutch 14th Annual Comprehensive Hematology & Oncology Review Course

R. Banerjee

Managing Newly Diagnosed MM in 2024

Indy Hematology Review

S. Usmani

ASH 2023 Insights: "Highlights in 1L MM - Quadruplet Therapies on a …

Insights from 2023 ASH Annual Meeting

A. Jakubowiak

Recent Updates on Blinatumomab in ALL: FDA Approval in 1L and Incorp…

Sarah Tasian

Will CAR-Ts and Bispecifics Replace HSCT in Myeloma?

MyCancerHaven

R. Vij, S. Al Hadidi